TABLE 5Baseline clinical and demographic characteristics of the OHTS-EGPS derivation cohort and the four validation cohorts

CharacteristicOHTS-EGPS control groupRotterdamMoorfieldsDunfermlineNottingham
No OAGOAGNo OAGOAGNo OAGOAGNo OAGOAGNo OAGOAG
Patientsa11471653652825444160281545
Age (years)56.1 (9.9)59.3 (9.5)56.0 (11.0)60.4 (10.2)59.3 (10.2)60.5 (10.5)62.9 (11.8)62.2 (9.2)60.9 (10.1)64.0 (9.4)
IOP (mmHg)24.0 (2.4)24.9 (2.7)25.3 (2.3)27.5 (2.5)22.4 (3.8)22.8 (3.3)24.4 (3.6)24.6 (3.6)22.3 (3.3)21.1 (3.4)
CCT (μm)577.0 (36.0)550.7 (36.3)574.9 (35.6)553.0 (27.9)558.8 (31.4)539.2 (26.8)NANA572.6 (43.7)538.1 (4.5)
VCD ratio (by contour)0.35 (0.2)0.43 (0.2)0.37 (0.16)0.55 (0.22)0.48 (0.15)0.50 (0.14)0.42 (0.18)0.50 (0.17)0.41 (0.15)0.48 (0.19)
PSD (dB)1.94 (0.4)2.01 (0.4)1.72 (0.36)1.89 (0.31)2.09 (1.00)2.26 (0.69)2.01 (0.82)2.16 (0.77)1.72 (1.22)2.11 (0.91)
CPSD (dB)1.14 (0.5)1.11 (0.5)NAbNA1.56 (1.16)b1.44 (1.00)NANANANA
Male504 (43.9)80 (48.5)173 (47.4)14 (50.0)149 (58.7)25 (56.8)89 (55.6)16 (57.1)76 (49.4)0
Racec
 Caucasian938 (82.4)121 (73.8)365 (100)28 (100)210 (82.7)36 (81.8)160 (100)28 (100)00
 A-A168 (14.8)33 (20.1)0013 (5.1)6 (13.6)0000
 Asian00004 (1.6)00000
 Other32 (2.8)10 (6.1)002 (0.8)2 (4.5)0000
 Unknown000025 (9.8)000154 (100)5 (100)
Diabetes (yes)120 (10.5)5 (3.0)NANANANA13 (8.1)4 (14.3)12 (7.8)0
Heart disease (yes)90 (7.8)19 (11.5)NANANANA8 (5.0)2 (7.1)12 (7.8)1 (20.0)
Treated (yes)d00244 (66.8)17 (60.7)126 (49.6)20 (45.5)3 (1.9)046 (30.1)e2 (40.0)

A-A, African ancestry; NA, not available.

Values are expressed as mean (SD) for continuous variables and as number (percentage) for categorical variables.

a

This is the number of patients available in each cohort. Owing to missing data (except for age), only a subset was used to compute the summary statistics. (see the OHTS-EGPS report64 and Table 3).

b

CPSD was measured in 232 patients who did not develop OAG and in all 44 patients who developed OAG.

c

For OHTS-EGPS, we grouped the Native American, Hispanic and other categories as Other; black, non-Hispanic as A-A; and white non-Hispanic as Caucasian. In the Moorfields cohort, African Caribbean was classified as A-A. Two patients in the Other category in the Moorfields cohort who did not develop OAG were Lebanese and Sri Lankan; the two in this category in this cohort who did develop OAG were Greek Cypriot and Egyptian.

d

Randomised to or prescribed an IOP-lowering treatment.

e

Based on 153 patients.

From: 4, Risk prediction tools for development of open-angle glaucoma

Cover of Surveillance for Ocular Hypertension: An Evidence Synthesis and Economic Evaluation
Surveillance for Ocular Hypertension: An Evidence Synthesis and Economic Evaluation.
Health Technology Assessment, No. 16.29.
Burr JM, Botello-Pinzon P, Takwoingi Y, et al.
Southampton (UK): NIHR Journals Library; 2012 Jun.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.